Anbio Biotechnology (NNNN) vs QuidelOrtho (QDEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
QuidelOrtho (QDEL) has outperformed Anbio Biotechnology (NNNN) over the past year, losing 55.5% versus a loss of 85.1%. QuidelOrtho is the larger company by market cap ($887.4 million vs $203.2 million), about 4.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NNNN | QDEL |
|---|---|---|
| Share price | $4.63 | $12.94 |
| Market cap | $203.22M | $887.37M |
| 1-day change | +0.22% | +4.26% |
| YTD return | -84.64% | -56.55% |
| 1-year return | -85.09% | -55.46% |
| 5-year return | — | -90.32% |
| P/E ratio (TTM) | 30.87 | — |
| Forward P/E | — | 8.97 |
| EPS (TTM) | $0.15 | $-15.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $44.73 | $35.58 |
| 52-week low | $4.55 | $9.92 |
| Distance from 52-week high | -89.65% | -63.63% |
| Analyst consensus | — | hold |
| Avg. price target upside | — | +13.37% |
| Average volume | 146.84K | 1.51M |
| Shares outstanding | 43.89M | 68.58M |
| Employees | 27 | 6,500 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- QuidelOrtho is about 4.4 times larger than Anbio Biotechnology by market value ($887.37M vs $203.22M).
- QDEL has outperformed NNNN by 29.6 percentage points over the past year.
About Anbio Biotechnology
NNNN stock →Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 27 employees
About QuidelOrtho
QDEL stock →QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 6,500 employees
NNNN vs QDEL FAQ
Which is bigger, Anbio Biotechnology or QuidelOrtho?
QuidelOrtho (QDEL) is larger, with a market capitalization of $887.37M compared with $203.22M for Anbio Biotechnology (NNNN).
Which stock has performed better over the past year, NNNN or QDEL?
QDEL returned -55.46% over the past 12 months, compared with -85.09% for NNNN (price return, excluding dividends). Past performance does not predict future results.
Are Anbio Biotechnology and QuidelOrtho in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.